摘要
目的:观察经肝动脉栓塞化疗(TACE)单用或联合替吉奥与沙利度胺治疗中晚期肝细胞癌(HCC)的疗效。方法:将2010年8月-2012年8月本院收治的无法手术切除的中晚期HCC患者80例随机分为2组,每组40例。治疗组采用TACE联合替吉奥与沙利度胺口服,对照组仅行TACE治疗。比较两组的有效率、疾病控制率、生存率以及不良反应情况。结果:治疗组有效率67.5%,对照组30.0%,差异有统计学意义(P=0.001);治疗组疾病控制率92.5%,对照组37.5%,差异有统计学意义(P=0.000)。治疗组1年生存率80.0%,对照组50.0%,差异有统计学意义(P=0.005);治疗组2年生存率42.5%,对照组10.0%,差异有统计学意义(P=0.001)。两组不良反应轻微,主要为恶心呕吐、便秘和骨髓抑制,为I、II级,对症治疗可缓解,两组比较差异无统计学意义(P>0.05)。结论:替吉奥与沙利度胺联合TACE术对中晚期HCC有一定的治疗价值,值得进一步观察。
Objective:To evaluate the clinical effect of transcatheter arterial chemoembolization( TACE)alone or combined with gimeracil and oteracil potassium(S-1)and thalidomide in treatment of advanced hepatocellular carci-noma( HCC). Methods:All 80 patients with unresectable advanced HCC,who were admitted to our hospital from Au-gust 2010 to August 2012,were randomly divided into treatment group(n=40)and control group(n=40). The treat-ment group was treated with TACE combined with S-1 and thalidomide,and the control group with TACE alone. The response rates,disease control rates,survival rates,and adverse reactions of both groups were evaluated. Results:Com-pared with the control group,the treatment group had a significant higher response rate(P =0. 001),a significant higher disease control rate(P=0. 000),a significant higher 1-year survival rate(P=0. 005),and a significant high-er 2-year survival rate(P=0. 001). Mild adverse reactions(grade I or II )were seen in two groups,including nausea,vomiting,constipation,and bone marrow suppression. These adverse reactions could be reduced by symptomatic treat-ment and showed no significant differences between the two groups(P〉0. 05). Conclusion:The combination therapy with S-1 and thalidomide plus TACE is effective in the treatment of advanced HCC and is worth further study.
出处
《现代肿瘤医学》
CAS
2015年第17期2475-2478,共4页
Journal of Modern Oncology
基金
江门市卫生系统医学科研立项(编号:13A027)
关键词
肝动脉栓塞化疗
替吉奥
沙利度胺
原发性肝癌
gimeracil and oteracil porassium
thalidomide
hepa-tocellular carcinoma